Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Los Bonos 1 (no aplicable en España), 2 (Marcas y Diseños) y 3 (patentes nacionales, patentes europeas, informes tecnológicos de patentes y búsquedas retrospectivas) se encuentran cerrados desde el 20/08/2025. La solicitud del Bono 4 sigue abierta. Más adelante se informará sobre la reapertura de estos Bonos
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
143
resultados
Última actualización
12/10/2025 [07:03:00]
Resumen de: WO2025211492A1
The present invention relates to a vaccine immune adjuvant that utilizes the synergy between imiquimod and a Nod2 receptor-stimulating component or a Nod2 receptor-stimulating bacterium. According to one aspect of the present invention, a vaccine immune adjuvant composition comprising, as active ingredients, imiquimod and a Nod2 receptor-stimulating component or a Nod2 receptor-stimulating bacterium can enhance the efficacy of a vaccine to be greater than that of the administration of imiquimod alone, and thus can be effectively used as a complex immune adjuvant for increasing immune responses of various vaccines such as an SARS-CoV-2 virus vaccine, an influenza A virus vaccine and an anticancer vaccine against melanoma.
Resumen de: US2025313611A1
Sarbecovirus binding agents, in particular antibodies and antigen-binding fragments thereof, which are capable of potently neutralizing a Sarbecovirus, in particular capable of neutralizing any one or both of SARS-COV-2, including SARS-COV-2 variants, and SARS-COV. 1. The binding agents, in particular the antibodies and antibody fragments, bind to heptad repeat 2 (HR2) domain of spike protein of the Sarbecovirus, more particularly to a quaternary epitope located within 2 adjacent HR2 domains. Also disclosed are methods using these binding agents and uses thereof.
Resumen de: US2025312345A1
Provided herein are compounds of formula (I) or (I-A), which act as non-covalent inhibitors of SARS-CoV2 main protease (Mpro). In certain embodiments, the compounds of formula (I) or (I-A) are useful in treating, ameliorating, and/or preventing COVID-19 infections, as well as reducing or ameliorating symptoms associated with COVID-19 infection.
Resumen de: US2025312370A1
Treatments for SARS-CoV-2 infection, COVID-19, symptoms of COVID-19, and similar infections. Specifically, treatments for patients identified as having Acute Respiratory Distress Syndrome (ARDS), and specifically COVID-19 ARDS, and/or suffering the effects of hypoxia. The treatments include increasing a patient's naturally occurring levels of ATP, adenosine, and/or other adenosine compounds.
Resumen de: AU2024229916A1
The present disclosure provides multivalent anti-spike protein binding molecules, comprising multimerization moieties linked to anti-spike protein antigen-binding domains, that specifically bind to RBD regions of SARS-CoV and/or SARS-CoV-2. The present disclosure further relates to the methods of producing the multivalent anti-spike protein binding molecules, pharmaceutical compositions comprising of the multivalent anti-spike protein binding molecules, and methods of use of the multivalent anti-spike protein binding molecules to treat conditions associated with SARS-CoV and SARS-CoV-2 infections, such as COVID-19.
Resumen de: WO2025210119A1
The present invention relates to panantiviral compounds, such as compounds providing a broad antiviral activity against a variety of viruses. More specifically the present invention relates to antiviral compounds directed against coronavirus and in particular SARS-type and MERS-type coronaviruses. More specifically, the present invention provides for the compounds PKI-179 and MTI-31 for use in a method of treatment, prevention or amelioration of a diseases or disorder caused by infection with a coronavirus such as SARS-CoV-2.
Resumen de: AU2024227880A1
The present disclosure provides ACE2 fusion proteins, comprising multimerization moieties linked to ACE2 moieties, that specifically bind to RBD regions of SARS-CoV and/or SARS-CoV-2. The present disclosure further relates to the methods of producing the ACE2 fusion proteins, pharmaceutical compositions comprising of the ACE2 fusion proteins, and methods of use of the ACE2 fusion proteins to treat conditions associated with SARS-CoV and SARS-CoV-2 infections, such as COVID-19.
Resumen de: EP4628100A2
This invention relates to the use of anti-viral drugs with different mechanisms of action for the treating or preventing of viral infections such as COVID-19 (also known as SARS-CoV-2) and reducing medical complications related to COVID-19 viral disease. The present invention also relates to compositions and combinations of new antiviral drugs formed from existing drugs with antiviral activity, and the administration of these compounds used in these various new combinations, that are incorporated into a pulmonary and oral delivery systems.
Resumen de: UA129995C2
Present invention relates to the field of pharmaceuticals, in particular to drugs for treatment of human infections caused by RNA viruses, namely to the compound 1-(6-oxy-2-oxahexyl)-2-trifluoromethylthiomethylbenzimidazole) (another name is 4-(2-{(trifluoromethyl)thiomethyl}-1H-benzimidazol-1-yl)methoxybutan-1-ol). The claimed compound is a twice-modified analog of natural nucleosides and has antiviral activity against RNA-genomic viruses, especially coronavirus and enterovirus. Invention also relates to pharmaceutical composition for treatment of infectious diseases caused by RNA virus, containing the compound 1-(6-oxy-2-oxahexyl)-2-trifluoromethylthiomethylbenzimidazole) in a pharmaceutically effective amount. The pharmaceutical composition according to present invention may comprise 1-(6-oxy-2-oxahexyl)-2-trifluoromethylthiomethylbenzimidazole) and drug ribavirin in a pharmaceutically effective amount at a ratio of 1:1. These pharmaceutical compositions may be used in treatment of coronavirus and enterovirus infections.
Resumen de: US2025304559A1
The invention relates to compounds of Formula Iand pharmaceutically acceptable salts thereof wherein R1, R2, R3, p, q, q′ and Ring A are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
Resumen de: US2025306023A1
A method and system for predicting/diagnosing inflammatory diseases, such as, multisystem inflammatory syndrome in children (MIS-C), Kawasaki disease, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), respiratory syncytial virus, an adenovirus, influenza A, B C, or D, and/or parainfluenza in a subject is described.
Resumen de: US2025303337A1
An apparatus used with supplied power for treating air in an environment and method of use. A housing is mobile in the environment and has an intake and an exhaust. At least one prime mover is disposed in the housing and is operable to move the air in the environment through the housing from the intake to the exhaust. At least one permeable barrier is disposed in the housing and is configured to impede the moved air flow therethrough up to an impedance threshold. The permeable barrier is in electrical communication to the supplied power and is heated to a surface temperature.
Resumen de: AU2024234831A1
In alternative embodiments, provided are pharmaceutical compositions and therapeutic combinations of drugs, including products of manufacture and kits, for treating, preventing or ameliorating (for example, decreasing the symptoms of, or decreasing the mortality of) a viral infection, for example, a coronavirus infection such as a COVID-19 or variant thereof, and methods for making and using same. In alternative embodiments, provided are products of manufacture and kits for delivering pharmaceutical compositions and therapeutic combinations of drugs as provided herein, for example provided are transdermal delivery devices such as patches that can have multiple compartments for delivering transdermally different drugs at the same time.
Resumen de: AU2024236771A1
The present invention relates to an in-vitro method for screening a subject, for determining the severity of Covid-19 outcome caused by Severe Acute Respiratory Syndrome Coronavirus 2(SARS-COV-2) using combination of gene signature comprising human RNA based biomarker and a kit thereof.
Resumen de: US2025302944A1
COMBINATION OF EPITOPES AND USE THEREOF, VACCINE CONSTRUCT, METHOD OF INDUCING AN IMMUNE RESPONSE, METHOD FOR THE IDENTIFICATION OF EPITOPES The present invention refers to a combination of epitopes comprising at least eight T cell epitopes from the SARS-CoV-2, as well as the use of said combination (“set of epitopes”). Said epitopes are widely recognized by CD4+ T-lymphocytes of the overwhelming majority of COVID-19 convalescent individuals.
Resumen de: US2025304996A1
The present invention relates to pseudotyped lentiviral vectors, particularly to pseudotyped with a modified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, as well as related constructs, methods and therapeutic indications.
Resumen de: US2025304659A1
The present disclosure is directed to antibodies binding to and neutralizing the coronavirus designated SARS-CoV-1 and methods for use thereof.
Resumen de: US2025304972A1
Novel compounds capable of blocking viral infections sustained by the SARS-Cov2 virus are provided. A method for preventing and/or treating infectious diseases caused by a virus involving administering the novel compounds is also provided.
Resumen de: WO2025201575A2
Disclosed in the present invention are an anti-SARS-CoV-2 arylnaphthalene lignan compound, and a preparation method therefor and the use thereof. Results show that ANL-1, ANL-2, and ANL-4 to ANL-7 have no toxicity to Vero E6 cells, and ANL-3 has low toxicity to Vero E6 cells. In a Vero E6 cell model, the in vitro anti-SARS-CoV-2 activities of ANL-7 and ANL-2, in TI value, are respectively 19 times and 16 times that of remdesivir, and are higher than the in-vitro anti-SARS-CoV-2 activity of a market-available drug. ANL-2 has a significant inhibitory effect on RNA-dependent RdRp activity of SARS-CoV-2, and ANL-2 also effectively limits the replication of various pathogenic coronaviruses in Caco2 cells or hamsters. It can be seen that the arylnaphthalene lignan compound has a good anti-coronavirus activity and can be used for treating and preventing SARS-CoV-2 infection or delaying the progress of SARS-CoV-2 infection in a patient.
Resumen de: WO2025203062A1
The present invention relates to the preparation of indole-based compounds in free form or an acceptable salt form potential therapeutic target as an antiviral agent against SARS-Cov2. The indole-based small molecules are, capable of antiviral activity in RT-qPCR and cell-based assay in SARS-CoV-2 infected VERO E6 cells, that may ultimately be used to achieve improved human health in patients against covid- 19 or other similar viral diseases.
Resumen de: WO2025207791A1
Aspects are directed to a novel small molecule inhibitor of Nsp16 having a chemical formula of (N-9-(2R,3R,4S,5S)-5-(chloromethyl)-3,4-dihydroxy-tetrahydrofuran-2-ylpurin-6-ylprop-2-enamide) (AT501) or analogs thereof. Other aspects are directed to a therapeutic composition comprising AT501 or analogs thereof, further including antiviral compounds or anticancer compounds. Certain aspects are directed to a method of treating Coronavirus infection by administering AT501 or a composition thereof to a subject having or at risk of obtaining a Coronavirus infection caused by SARS-CoV-1 or SARS-CoV-2 virus. Certain aspects are directed to methods of treating cancer by administering AT501 or a composition thereof to a subject having or at risk of developing cancer, such as leukemia.
Resumen de: WO2025208143A1
Compositions and methods for treating a viral condition. The composition is administered to the subject in a therapeutic amount. The composition includes a first medicament effective for up-regulating disulfide bond donation and exchange, and a second medicament comprising a DNA polymerase inhibitor, a protease inhibitor, a DNA/RNA inhibitor, an intron splicer, or combinations thereof. The first medicament is effective for causing viruses to dissociate from integration sites and actively replicate with availability of disulfide bonds. The second medicament is effective for supporting or improving degradation, slicing, and/or inhibition of viral RNA, viral DNA, and/or viral proteins. The virus is Coronavirus, Epstein Barr virus, human papillomavirus, or herpes simplex virus.
Resumen de: WO2025202219A1
The present invention relates to the use of Melanoma Differentiation-Associated protein (MDA5) inhibitors for enhancing the number of p16high immune cells in vitro or in a patient in need thereof, in particular to extend health span and protect tissues against aging. It is moreover herein reported that p16high immune cells surprisingly play a key role in establishing disease tolerance, and can be useful for counteracting different lethal conditions, including LPS-induced sepsis, acute lethal SARS-CoV-2 infection, cancer and ionizing irradiation. Mechanistically, it is shown that inhibition of MDA5 induces an increase in p16high immune cells subsets that, in turn, establishes a low adenosine environment and disease tolerance. The present invention also relates to a pharmaceutical composition comprising immune cells such as CAR-T cells in which the MDA5 expression and/or activity is inhibited, and its use for various therapeutic purposes.
Resumen de: WO2025202222A1
The present invention relates to the use of a STING agonist, of a TLR5 agonist or of a TLR7 agonist for enhancing the number of p16high immune cells in vitro or in a patient in need thereof, in particular to extend health span and protect tissues against aging. It is also herein reported that p16high immune cells surprisingly play a key role in establishing disease tolerance, and can be useful for counteracting different lethal conditions, including LPS-induced sepsis, acute lethal SARS-CoV-2 infection, cancer and ionizing irradiation. The present invention thus relates to a pharmaceutical composition comprising autologous or heterologous p16high immune cells such as p16high CAR-T cells, and its use for various therapeutic purposes. These cells are preferably obtained by contacting them with a STING agonist, a TLR5 agonist and/or a TLR7 agonist.
Nº publicación: MX2025009564A 01/10/2025
Solicitante:
VDF FUTURECEUTICALS INC [US]
VDF FUTURECEUTICALS, INC
Resumen de: MX2025009564A
A polyphenol-rich composition is orally administered to alleviate a sign or symptom of a post-viral syndrome, and preferably post-COVID syndrome. Most typically, the composition comprises at least 50 wt% total catechins, at least 20 wt% total chlorogenic acids, and optionally up to 30 wt% total supplemental antioxidants. The composition may be formulated from a green coffee bean extract, a green tea extract, a turmeric extract, a tart cherry or extract thereof, a broccoli or extract thereof, and a kale or extract thereof. Notably, such compositions were effective in individuals post SARS-CoV2 infection to reduce proinflammatory cytokines and interleukins, increase NOHb, and to reduce reactive oxygen species due to mitochondrial dysfunction, iNOS activity, and NOX2 activity.
BOPI
Sede Electrónica
